Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. - Wikidata - wikimedia - TriplyDB

Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection.

Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection.

http://www.wikidata.org/entity/Q40852082

about

Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks Antiviral L-nucleosides specific for hepatitis B virus infection Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus In vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration.Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks.Aging and HIV/AIDS: pathogenetic role of therapeutic side effects Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors.The woodchuck model of hepatitis B virus infection.Anti-HBV specific beta-L-2'-deoxynucleosides.Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis.Do preclinical testing strategies help predict human hepatotoxic potentials?Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.Inhibition of hepatitis B virus by a novel L-nucleoside, beta-L-D4A and related analogues.Targets of emerging therapies for viral hepatitis B and C.Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection.Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.Animal models of idiosyncratic drug-induced liver injury--current status.Experimental models and therapeutic approaches for HBV.Regulatory Forum Opinion Piece*: Use and Utility of Animal Models of Disease for Nonclinical Safety Assessment: A Pharmaceutical Industry Survey.Current challenges and controversies in drug-induced liver injury.Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks.Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle.An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax).

P2860

Q28344296-3BDAA255-DC2B-41AC-8E6F-F40EE7CB2C4B Q28345251-B300DCB2-B79D-4ED9-A729-45752A345EE6 Q28360714-148D1A01-4E9A-467F-995F-608C3F42215B Q30885827-A06E1830-E1C7-4E6E-B1FD-C798CE9B9DC8 Q33419607-8D9DE847-F9E0-4132-911E-BB137BD0F14E Q33700651-A87AA7C0-4FA8-49A2-8A4B-BEB90610A740 Q33787525-5D774287-0CF5-452D-A163-7611F016D22D Q33883722-D0804B5E-C451-479D-AFF1-FE379F538940 Q33883757-458BC283-710F-405B-A635-2B4E37AC3289 Q33980098-6DCEA19D-16DB-4583-B7BC-7335E2E2FB7F Q33983079-1ED9A22C-553F-452B-ABF7-7FC90B523380 Q34077043-C8B1DDBB-CB0B-40F9-94C1-5AAED5C08615 Q34089694-D8CF5A44-953D-48D4-BD30-4B7A02A673C2 Q34282667-C6A449CD-53F3-4D3A-ABB7-8B57B170AD45 Q34282796-721F782F-2595-48D2-94C1-08F781A57E11 Q34373564-35390C0B-68B4-4A77-8B35-CA8A6614FA1C Q34932672-6749CC98-077F-437F-B36C-324B6F9E5604 Q35606742-266A8342-9AD1-4C93-AA34-3796C6E965BE Q36086429-39BDCB77-CF62-43B9-98CE-BC5D2D290A4D Q36094811-22538A68-7A69-466C-84DE-292C95765A0E Q36178977-904572D1-A489-4720-84E2-194AE80CCBBF Q36653655-3823CEC3-A82F-4859-B47C-74DCE63307BB Q36932959-C6782229-70C2-423B-9C0D-D082E63FB459 Q37099867-F07BA0FA-C178-4DAF-8C02-F609C4190852 Q37239515-0CFE235C-61B1-40AE-994D-00EB55E225B8 Q37638755-D5BF54A8-8B8E-423B-A9BF-6247B89D2238 Q37897219-EA975C9F-C545-478F-A804-FAA45BE7AE19 Q38035173-34A3D9EB-E2E3-4467-9E56-37E65E4619AC Q38870693-C7152A4D-1DEE-4752-B5F6-E1780A4331CF Q39523252-336B528C-71E7-49E0-B93A-97017FDEE1C7 Q39559680-ADC3DE00-A1D5-453B-9D91-D2806BCEC72C Q40619887-86D44B1C-05B9-40A4-BDCF-05B4AB34CAB9 Q41883516-2C7552F7-B709-431B-B6A9-C31CDAC8FDC3 Q42004056-CA8D34AB-75DC-4A92-8DFA-18FC544276EE Q43136598-F05D102D-4EF6-42CF-9EE9-1926E52918E2 Q43195715-ECEBBA13-DCE3-473A-8155-6B87291E278E Q54177011-83F2E3D1-B0EE-430C-B930-4691AADBF37C

P2860

Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection.

http://www.wikidata.org/entity/Q40852082

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh

1998年學術文章

@zh-hant

name

Antiviral activity and toxicit ...... f hepatitis B virus infection.

@en

type

label

Antiviral activity and toxicit ...... f hepatitis B virus infection.

@en

prefLabel

Antiviral activity and toxicit ...... f hepatitis B virus infection.

@en

P1433

Q40852082-5EFFC260-07F5-4C73-84D8-BE9A5FF32627

P1476

Q40852082-1A896BC0-58DC-40EC-A6F2-03E91C553A22

P2093

Q40852082-05D7CB27-29CA-4BD0-AEC4-02B6893C1559

Q40852082-07161E74-431F-480F-B4D9-AEC98387FDA1

Q40852082-077FC612-6002-4293-8958-1C6AAC829FA2

Q40852082-09BEF17A-CA7D-496D-8F70-03889ACE1A5B

Q40852082-0DFBBC4B-6D9B-42BB-8DA9-75C0A738010B

Q40852082-1AA9B55F-A00D-4B7D-A27C-F45984841950

Q40852082-4446D491-007F-400E-A354-C4A8E93CDFBB

Q40852082-4C693A6E-A24F-4353-84E1-7664205E3F55

Q40852082-5BCDC249-F526-4068-A9FF-8614DAEDBB9E

Q40852082-61D251E6-65A9-410F-97CA-42E5B7CD7867

P304

Q40852082-FE2681EA-109A-4DDF-A07C-AA3EEE19EDD9

P31

Q40852082-565BAFA3-F353-4994-8CEF-A69E0228DD2C

P356

Q40852082-68CF512F-9B69-407D-85F2-9F5B6CF47E2F

P407

Q40852082-1FA760C6-14DF-42EC-AEA9-C2BED3162C3F

P433

Q40852082-E067B6D9-56E9-47F4-9E5F-0274F5E3F17E

P478

Q40852082-ED5FF8F3-E13E-4364-BE29-0EE0A84B6C98

P577

Q40852082-D877A628-675D-460A-ACFA-65DCA35EF106

P5875

Q40852082-471F498D-4254-47A0-8101-867236F20132

P698

Q40852082-86ADB470-C45C-4BD4-AFA5-88593EAEC6C5

P356

P1433

P1476

Antiviral activity and toxicit ...... f hepatitis B virus infection.

@en

P2093

Ascenzi MA

http://www.w3.org/2001/XMLSchema#string

Baldwin BH

http://www.w3.org/2001/XMLSchema#string

Bowsher RR

http://www.w3.org/2001/XMLSchema#string

Colacino JM

http://www.w3.org/2001/XMLSchema#string

Cote PJ

http://www.w3.org/2001/XMLSchema#string

Engelhardt JA

http://www.w3.org/2001/XMLSchema#string

Erb HN

http://www.w3.org/2001/XMLSchema#string

Gerin JL

http://www.w3.org/2001/XMLSchema#string

Graham LA

http://www.w3.org/2001/XMLSchema#string

Hornbuckle WE

http://www.w3.org/2001/XMLSchema#string

P304

179-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.510280124

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

1998-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229667944

http://www.w3.org/2001/XMLSchema#string

P698

9657111

http://www.w3.org/2001/XMLSchema#string